Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Open access
Di Stefano, Anna Luisa, Fucci, Alessandra, Frattini, Veronique, Labussiere, Marianne, Mokhtari, Karima, Zoppoli, Pietro, Marie, Yannick, Bruno, Aurelie, Boisselier, Blandine, Giry, Marine, Savatovsky, Julien, Touat, Mehdi, Belaid, Hayat, Kamoun, Aurelie, Idbaih, Ahmed, Houillier, Caroline, Luo, Feng R., Soria, Jean-Charles, Tabernero, Josep, Eoli, Marica, Paterra, Rosina, Yip, Stephen, Petrecca, Kevin, Chan, Jennifer A., Finocchiaro, Gaetano, Lasorella, Anna, Sanson, Marc, Iavarone, Antonio·2015·Clinical Cancer Research

Abstract

Purpose: Oncogenic fusions consisting of fibroblast growth factor receptor (FGFR) and TACC are present in a subgroup of glioblastoma (GBM) and other human cancers and have been proposed as new therapeutic targets. We analyzed frequency and molecular features of FGFR–TACC fusions and explored the therapeutic efficacy of inhibiting FGFR kinase in GBM and grade II and III glioma. Experimental Design: Overall, 795 gliomas (584 GBM, 85 grades II and III with wild-type and 126 with IDH1/2 mutation) were screened for FGFR–TACC breakpoints and associated molecular profile. We also analyzed expression of the FGFR3 and TACC3 components of the fusions. The effects of the specific FGFR inhibitor JNJ-42756493 for FGFR3–TACC3–positive glioma were determined in preclinical experiments. Two patients with advanced FGFR3–TACC3–positive GBM received JNJ-42756493 and were assessed for therapeutic response. Results: Three of 85 IDH1/2 wild-type (3.5%) but none of 126 IDH1/2-mutant grade II and III gliomas harbored FGFR3–TACC3 fusions. FGFR–TACC rearrangements were present in 17 of 584 GBM (2.9%). FGFR3–TACC3 fusions were associated with strong and homogeneous FGFR3 immunostaining. They are mutually exclusive with IDH1/2 mutations and EGFR amplification, whereas they co-occur with CDK4 amplification. JNJ-42756493 inhibited growth of glioma cells harboring FGFR3–TACC3 in vitro and in vivo. The two patients with FGFR3–TACC3 rearrangements who received JNJ-42756493 manifested clinical improvement with stable disease and minor response, respectively. Conclusions: RT-PCR sequencing is a sensitive and specific method to identify FGFR–TACC–positive patients. FGFR3–TACC3 fusions are associated with uniform intratumor expression of the fusion protein. The clinical response observed in the FGFR3–TACC3–positive patients treated with an FGFR inhibitor supports clinical studies of FGFR inhibition in FGFR–TACC–positive patients. Clin Cancer Res; 21(14); 3307–17. ©2015 AACR. See related commentary by Ahluwalia and Rich, p. 3105

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2199

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 293

Metadata

Authors
Di Stefano, A. L., Fucci, A., Frattini, V., Labussiere, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., Savatovsky, J., Touat, M., Belaid, H., Kamoun, A., Idbaih, A., Houillier, C., Luo, F. R., Soria, J.-C., Tabernero, J., Eoli, M., Paterra, R., Yip, S., Petrecca, K., Chan, J. A., Finocchiaro, G., Lasorella, A., Sanson, M., & Iavarone, A.
Venue
Clinical Cancer Research
Published
2015-07-14
Volume
21
Issue
14
Pages
3307-3317
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2008550171
Cited by
293
References
38
FWCI
15.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2199
The paper
Di Stefano, A. L., Fucci, A., Frattini, V., Labussiere, M., Mokhtari, K., Zoppoli, P., Marie, Y., Bruno, A., Boisselier, B., Giry, M., Savatovsky, J., Touat, M., Belaid, H., Kamoun, A., Idbaih, A., Houillier, C., Luo, F. R., Soria, J.-C., Tabernero, J., . . . Iavarone, A. (2015). Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2199

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.